Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 319

Sales Development Drugs 319

Bio Pharma Dive

JANUARY 14, 2025

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

Sales 304

Sales Drugs 304

Bio Pharma Dive

APRIL 30, 2024

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

Sales 297

Sales Production Drugs 297

Bio Pharma Dive

OCTOBER 18, 2021

The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.

Sales 281

Sales Drugs Medicine 281

Bio Pharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

Sales 296

Sales Production Drugs 296

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 281

Sales Medicine Drugs Marketing 281

Bio Pharma Dive

OCTOBER 28, 2021

Executives based their projections on contracts already in place for the drug, known as molnupiravir. But sales could climb even higher if it works as a preventive treatment too.

Sales 310

Sales Drugs 310

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 303

Sales Drugs 303

Bio Pharma Dive

OCTOBER 1, 2020

An 18-month investigation by the House Oversight Committee targeted the pricing practices behind the top-selling drugs Revlimid and Copaxone.

Sales 324

Sales Drugs 324

Bio Pharma Dive

MAY 2, 2024

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Sales 248

Sales Drugs 248

Bio Pharma Dive

FEBRUARY 3, 2022

Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.

Sales 271

Sales Doctors Doctor Drugs 271

Pharmaceutical Technology

AUGUST 9, 2024

Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.

Sales 246

Sales Drugs 246

Bio Pharma Dive

DECEMBER 5, 2022

The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market.

Sales 297

Sales Drugs Marketing 297

Pharmaceutical Technology

MARCH 2, 2023

Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

Bio Pharma Dive

MARCH 14, 2024

But its sales potential is unclear, and competition could emerge from popular weight loss drugs. Rezdiffra’s clearance is a turning point in the fight against the liver disease.

FDA Approval 323

FDA Approval Drugs Sales 323

Bio Pharma Dive

NOVEMBER 2, 2022

Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.

Manufacturing 297

Manufacturing Sales Medicine Drugs 297

Bio Pharma Dive

JANUARY 11, 2023

Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort.

FDA Approval 319

FDA Approval Drugs Sales Medicine 319

Bio Pharma Dive

AUGUST 7, 2024

Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.

Sales 276

Sales Drugs Marketing 276

Bio Pharma Dive

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Sales Drugs 246

Bio Pharma Dive

MAY 21, 2024

drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.

Sales 260

Sales Drugs Development 260

Bio Pharma Dive

SEPTEMBER 30, 2021

The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts.

Sales 346

Sales Drugs 346

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 10, 2024

In order to avoid environmental hazards due to pharmaceutical products, the Department of Pharmaceuticals (DoP) is thinking of framing a ‘Disposal Policy’ for removing the unused and date-expired drugs from the sale premises and from the households.

Sales 188

Sales Drugs Production Clinical Trials 188

Bio Pharma Dive

FEBRUARY 17, 2022

The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.

Sales 327

Sales Drugs 327

Bio Pharma Dive

JULY 15, 2022

In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.

Drugs 310

Drugs Sales 310

Bio Pharma Dive

JULY 29, 2022

Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

Sales 290

Sales Medicine Drugs Marketing 290

Bio Pharma Dive

SEPTEMBER 27, 2023

Laboratoires Théa terminated its planned purchase of ProQR’s sepofarsen after certain ProQR personnel opted against working for the French company.

Sales 289

Sales Drugs 289

Bio Pharma Dive

APRIL 2, 2024

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Sales 297

Sales Marketing Drugs 297

Bio Pharma Dive

NOVEMBER 1, 2022

Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.

Sales 297

Sales Drugs 297

Bio Pharma Dive

FEBRUARY 17, 2021

The Swiss drugmaker's pill Entresto is now cleared in the U.S. for use in patients with stronger hearts, expanding the eligible population by two-thirds.

Sales 273

Sales Drugs 273

Pharmaceutical Technology

NOVEMBER 8, 2024

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.

Drugs 264

Drugs Sales 264

Bio Pharma Dive

JANUARY 12, 2021

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.

Antibody 301

Antibody Vaccination Vaccine Drugs 301

Bio Pharma Dive

JULY 12, 2022

A former Celgene executive, Jackie Fouse has led Agios since 2019, overseeing its transformation into a company focused solely on uncommon diseases. In August, she will transition to chair its board of directors.

Sales 315

Sales Drugs 315

Bio Pharma Dive

APRIL 23, 2024

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

Sales 173

Sales Drugs 173

Bio Pharma Dive

MARCH 13, 2023

In its first full quarter on the market, Amylyx’s Relyvrio generated revenue just shy of $22 million, or roughly five times what some analysts were forecasting a month ago.

Sales 238

Sales Drugs Marketing 238

Bio Pharma Dive

APRIL 24, 2024

Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.

Sales 314

Sales Drugs 314

Bio Pharma Dive

JULY 12, 2024

Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

Sales 173

Sales Licensing Licensing Drugs 173

Bio Pharma Dive

OCTOBER 25, 2022

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

Gene Therapy 289

Gene Therapy Sales Gene Marketing 289